FDA Approves Technivie for Hepatitis C

Share this content:
FDA Approves Technivie for Hepatitis C
FDA Approves Technivie for Hepatitis C

(HealthDay News) -- Technivie (ombitasvir, paritaprevir and ritonavir) has been approved by the U.S. Food and Drug Administration, in tandem with ribavirin, to treat hepatitis C genotype 4 infection among people without cirrhosis and without scarring.

Technivie is the first drug to be sanctioned to treat genotype 4 hepatitis C infection without requiring co-use of the drug interferon, the agency said Friday in a news release.

The Technivie/ribavirin combination was evaluated in a clinical study involving 135 people. Of the participants who received Technivie with ribavirin, 100 percent achieved a sustained virologic response, while 91 percent of those who received Technivie without ribavirin achieved a sustained virologic response. The most commonly reported side effects included fatigue, asthenia, nausea, insomnia, pruritus, and other skin reactions.

Technivie's label includes a warning of the possibility of elevated liver enzymes, a result that occurred most often among women who took contraceptives containing ethinyl estradiol. Such contraceptives should be discontinued before these women take Technivie, the FDA advised.

Technivie is marketed by AbbVie, based in North Chicago.

More Information

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease


More in Home

Hormonal Contraception May Raise Depression Risk

Hormonal Contraception May Raise Depression Risk

Study also ties hormonal patches, IUDs to greater antidepressant use, especially in teens

Dose-Dependent Link Between Cannabis Use, Psychosis Relapse

Dose-Dependent Link Between Cannabis Use, Psychosis Relapse

But researchers note effect is small, and the research isn't definitive

Systolic Blood Pressure Variability Linked to Mortality, Morbidity

Systolic Blood Pressure Variability Linked to Mortality, Morbidity

Increased SBP variability tied to mortality, coronary heart disease, stroke, end-stage renal disease

is free, fast, and customized just for you!

Already a member?

Sign In Now »